ModernaTX granted US patent for SARS-CoV-2 mRNA domain vaccines.
The filing
On November 10, 2026, the USPTO granted patent 12788808 to ModernaTX, Inc. for coronavirus ribonucleic acid (RNA) vaccines and methods of using them. The disclosed vaccines are compositions that encode specific domains and subunits of the coronavirus.
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.